May 29, 2020
I’m excited to share this announcement with our Tulip Family of Customers. Black Tie Medical, Inc., the parent company of Tulip Medical Products, has sponsored a first-in-human clinical trial on the Potential Use of Cellular Stromal Vascular Fraction in Post-COVID-19 Pulmonary Injury and Adult Respiratory Distress Syndrome. Dr. Robert W. Alexander, a long-time member of Tulip’s Advisory Board and a pioneer in the field of adipose regenerative therapies, is the Principle Investigator. Read the published paper about this ground-breaking trial in the Journal of Current Medical Research and Opinion (CMRO):
FULL STUDY
In addition to sponsoring the trial and funding patient expenses, Tulip is donating the single-use instrumentation for harvesting the adipose tissue needed to treat these patients. It is enriching to re-direct a portion of our revenues to this exciting and timely project. The trial begins in June. For more information, contact Dr. Robert W. Alexander at rwamd1914@gmail.com.
--
Marcille Pilkington
President and CEO, Tulip Medical Products
